Biologics, Inc.
Cary, NC Doing business as Biologics By Mckesson Part of Mckesson Corporation
- UEI
- GVRYEDLFU6J3
- CAGE
- 6LEB9
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, McKesson Corporation, ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
Parent
Irving, TX
S1RUKWWRYFL6
-
Parent
Irving, TX
S1RUKWWRYFL6
- SAM.gov registration date
- Physical address
- 11800 Weston Pkwy, Cary, NC 27513, USA
- Website
- mckesson.com
- Founded
- 1833
- Employees
- 50K-100K
- Estimated annual revenue
- $10B+
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $205,539 |
| FY2025 | $379,741 |
| FY2024 | $21,536 |
| FY2023 | -$3,741 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Justice | $186,308 | |
| 2 | Department of Veterans Affairs | $19,231 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Helsinn Therapeutics (U.s.), Inc. | Woodbridge Township, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| Foundation Care LLC | Chesterfield, MO | 456110 Pharmacies and Drug Retailers |
| Mckesson Plasma And Biologics LLC | Shepherdsville, KY | 325412 Pharmaceutical Preparation Manufacturing |
| Covermymeds Pharmacy LLC | Memphis, TN | 456110 Pharmacies and Drug Retailers |
| Daiichi Pharmaceutical Corp | Bernards, NJ | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Biologics, Inc., doing business as Biologics By McKesson, operates as a for-profit pharmaceutical distributor supplying specialty cancer medications and biologics to federal healthcare and correctional facilities as a prime contractor, leveraging its position as a subsidiary of McKesson Corporation. Biologics competes exclusively in full-and-open procurements with no set-aside designations across 178 awards with combined potential value of $3.2 million.
The vendor's capability portfolio centers on specialty pharmaceutical supply: Lenalidomide (for multiple myeloma and lymphomas), Turalio (pexidartinib, a tyrosine kinase inhibitor for tenosynovial giant cell tumors), Caprelsa (vandetanib, a kinase inhibitor for medullary thyroid cancer), Ayvakit, and Xermelo, delivered through firm fixed-price purchase orders. Representative prime awards include a $286 thousand specialty medication contract with Federal Correctional Complex Butner (April 2026), multiple Lenalidomide orders to Veterans Integrated Service Network 21 totaling approximately $126 thousand (September–December 2025), and recurring monthly cancer drug biologics purchase orders to Federal Medical Center Carswell at $22 thousand per order (October 2024–May 2025).
Customer concentration is split between the Department of Veterans Affairs and the Department of Justice Bureau of Prisons, accounting for 51% of awards by count and 57% by potential value. Veterans Integrated Service Network 19 leads with 34 awards and $493 thousand combined potential value, followed by Federal Medical Center Lexington (14 awards, $490 thousand) and Federal Correctional Complex Butner (8 awards, $359 thousand). The vendor holds no parent contract vehicles; all work flows through direct purchase orders to individual federal healthcare and correctional institutions. Activity averaged roughly two to four awards annually from 2023 to 2024, then increased to 13 awards in 2025; one award has closed in 2026. Only one award (the April 2026 Federal Correctional Complex Butner order) reaches ultimate completion within the next twenty-four months, representing $286 thousand in recompete exposure.
Biologics operates as a wholly owned subsidiary of McKesson Corporation, a major healthcare services and IT provider that holds its own indefinite-delivery contracts with federal agencies including the Indian Health Service and the Department of Veterans Affairs. All 178 awards in Biologics' portfolio are prime awards; the vendor does not subcontract. Place of performance is listed as Cary, North Carolina, matching Biologics' headquarters address.
Quick answers
Is Biologics, Inc. registered in SAM.gov?
Yes. Biologics, Inc.'s SAM.gov registration is active through September 23, 2027.
How much has Biologics, Inc. received in federal contracts?
Federal contracts obligated $379,741 to Biologics, Inc. in fiscal year 2025 and $603,075 in fiscal years 2023 through 2027.
How does Biologics, Inc. rank among federal contractors?
Biologics, Inc.'s parent company, McKesson Corporation, ranked #1 in PSC 65, #1 in NAICS 325 and #2 at the Department of Justice in FY2025.
What is Biologics, Inc.'s most recent federal award?
Biologics, Inc.'s most recent federal contract award is Specialty medication (15B10626P00000273), from Federal Correctional Complex Butner (BOP), on April 3, 2026.
On GovTribe
See Biologics, Inc.'s full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors